Multiple Myeloma: Minimal Residual Disease Testing as an End Point Treatment

Multiple Myeloma: Minimal Residual Disease Testing as an End Point Treatment

Most multiple myeloma patients, even those in complete response, may show signs of relapse at some point of time. So, testing and quantifying Minimal Residual Disease (MRD) has become essential to obtain better prognostic correlations. Researchers believe that MRD testing could help them compare myeloma therapy strategies, evaluate new treatments faster, and guide treatment decisions. The myeloma panelists are talking to Dr. Ola Landgren, a lead researcher in the field, on what MRD testing could mean to your treatment, and about how MRD testing could become a new and earlier end-point in myeloma treatment.

Panelists

Talk Recorded on Aug. 31, 2017, 6 p.m.   EST 868 6

Hear Talk Audio




  • Anonymous User Aug. 31, 2017, 6:40 p.m.  US/Eastern

    Do we have adequate immunophenotyping to identify the patients who are in CT, but MRD post, that we predict will stay stable ( MGUS like) without further treatment?

  • Anonymous User Aug. 31, 2017, 5:56 p.m.  US/Eastern

    Do you expect blood biopsies to resolve the issue of sample bias with a BMB, and if so when will that be used in clinical trials?

  • Anonymous User Aug. 31, 2017, 12:42 a.m.  US/Eastern

    After my first year's treatment in a clinical trial ending this April and brought my Stage III high risk myeloma into SCR, an MRD test was performed. I was disappointed to learn that they couldn't use the MRD results. There was either a problem with the sample or the test. Is MRD an important enough tool that I should get it done again soon, perhaps at another center?

  • Anonymous User Aug. 30, 2017, 5:16 p.m.  US/Eastern

    Of the tests available now, which is the most sensitive to detect relapse? How often do you recommend testing? What is the recommendation for bone survey/MRI to check for lesions. My husband had a PET SCAN and a bone survey at diagnosis. It was never made clear to us what it showed, but no major tumors, primarily lytic lesions. Bone survey repeated after treatment showed a possible myeloma "lesion" left humerus, this was after reach CR. None of the doctor's seemed concerned to follow up on this. Also we were told no PET scan would be repeated after treatment. Guess insurance doesn't pay for it. Not sure I understand PET SCAN at diagnosis and no follow up for comparison. Anxious for improved MRD testing.

  • Anonymous User Aug. 30, 2017, 10:04 a.m.  US/Eastern

    Is any type of MRD testing available now or is it all still in the research stage? At what point would this type of testing be done? Are there any clinical trials for MRD? My husband is 20 months post tandem sct having achieved CR. Until MRD is developed and soc, what do you recommend for type and frequency of monitoring for relapse?

  • Anonymous User Aug. 29, 2017, 9:17 p.m.  US/Eastern

    Is it possible to get a transcript of the talk re MRD? Liz Gregory lizegregory@gmail.com